Stock Traders Buy High Volume of Put Options on Mylan N.V. (MYL)

Mylan N.V. (NASDAQ:MYL) was the target of some unusual options trading activity on Thursday. Traders purchased 15,303 put options on the stock. This is an increase of 638% compared to the average volume of 2,073 put options.

MYL has been the topic of several research reports. Zacks Investment Research raised shares of Mylan N.V. from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Cowen and Company reissued a “market perform” rating and issued a $43.00 price target (down from $55.00) on shares of Mylan N.V. in a research note on Sunday, May 21st. BidaskClub downgraded shares of Mylan N.V. from a “hold” rating to a “sell” rating in a research note on Saturday. Royal Bank Of Canada reissued a “hold” rating and issued a $33.00 price target (down from $41.00) on shares of Mylan N.V. in a research note on Friday, August 4th. Finally, Deutsche Bank AG decreased their price target on shares of Mylan N.V. from $52.00 to $51.00 and set a “buy” rating on the stock in a research note on Tuesday, April 18th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. Mylan N.V. currently has an average rating of “Buy” and an average target price of $49.40.

In other Mylan N.V. news, insider Anthony Mauro sold 10,000 shares of the stock in a transaction on Friday, June 9th. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the transaction, the insider now directly owns 140,653 shares of the company’s stock, valued at $5,626,120. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, President Rajiv Malik sold 25,000 shares of the stock in a transaction on Friday, June 9th. The shares were sold at an average price of $40.00, for a total transaction of $1,000,000.00. Following the transaction, the president now directly owns 799,855 shares in the company, valued at $31,994,200. The disclosure for this sale can be found here. Company insiders own 0.69% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Sheaff Brock Investment Advisors LLC purchased a new position in shares of Mylan N.V. during the second quarter valued at about $210,000. Quinn Opportunity Partners LLC boosted its position in shares of Mylan N.V. by 4.6% in the second quarter. Quinn Opportunity Partners LLC now owns 118,215 shares of the company’s stock valued at $4,589,000 after buying an additional 5,208 shares during the period. Los Angeles Capital Management & Equity Research Inc. boosted its position in shares of Mylan N.V. by 47.1% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 89,795 shares of the company’s stock valued at $3,486,000 after buying an additional 28,745 shares during the period. Vivaldi Asset Management LLC purchased a new position in shares of Mylan N.V. during the second quarter valued at about $5,098,000. Finally, Northern Capital Management LLC boosted its position in shares of Mylan N.V. by 3.0% in the second quarter. Northern Capital Management LLC now owns 13,800 shares of the company’s stock valued at $536,000 after buying an additional 400 shares during the period. Hedge funds and other institutional investors own 70.19% of the company’s stock.

Shares of Mylan N.V. (NASDAQ:MYL) traded up 0.91% during mid-day trading on Wednesday, hitting $32.08. 32,038,119 shares of the stock traded hands. Mylan N.V. has a one year low of $29.58 and a one year high of $50.40. The stock has a 50-day moving average of $38.42 and a 200 day moving average of $39.28. The stock has a market cap of $17.19 billion, a PE ratio of 32.05 and a beta of 1.27.

Mylan N.V. (NASDAQ:MYL) last released its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share for the quarter, missing analysts’ consensus estimates of $1.18 by $0.08. Mylan N.V. had a return on equity of 23.69% and a net margin of 4.59%. The company had revenue of $2.96 billion for the quarter, compared to analyst estimates of $3 billion. During the same period in the previous year, the business posted $1.16 EPS. The firm’s quarterly revenue was up 15.7% compared to the same quarter last year. Equities analysts predict that Mylan N.V. will post $5.12 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “[[title]]” was first posted by [[site]] and is the property of of [[site]]. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at [[permalink]].

Mylan N.V. Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.